U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C35H53NO3
Molecular Weight 535.8002
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TOCOPHERYL NICOTINATE

SMILES

CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@]1(C)CCC2=C(O1)C(C)=C(C)C(OC(=O)C3=CN=CC=C3)=C2C

InChI

InChIKey=MSCCTZZBYHQMQJ-AZAGJHQNSA-N
InChI=1S/C35H53NO3/c1-24(2)13-9-14-25(3)15-10-16-26(4)17-11-20-35(8)21-19-31-29(7)32(27(5)28(6)33(31)39-35)38-34(37)30-18-12-22-36-23-30/h12,18,22-26H,9-11,13-17,19-21H2,1-8H3/t25-,26-,35-/m1/s1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.springboard4health.com/notebook/v_e.html and http://www.ncbi.nlm.nih.gov/pubmed/2134664

Tocopherol (alpha tocopheryl nicotinate) is an ester of tocopherol and nicotinic acid. Vitamin E (Tocopherol) is sold commercially as the esterified form (alpha tocopheryl acetate, alpha tocopheryl succinate and alpha tocopheryl nicotinate). Alpha tocopheryl nicotinate has antioxidant and vasodilatory properties. It can be used as a mild warming agent, without producing the redness typical for nicotinic acid. Tocopherol (alpha tocopheryl nicotinate) has been available in Japan since 1967. Tocopherol under the brand name Juvela N is approved in Japan for the treatment of symptoms accompanying hypertension, hyperlipidemia, peripheral circulatory disturbance resulting from arteriosclerosis obliterans. Tocopherol has being shown to inhibit platelet aggregation.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Juvela N

Approved Use

Accompanying symptoms resulting from the following Hypertension Hyperlipidemia Peripheral circulatory disturbance resulting from the following Arteriosclerosis obliterans

Launch Date

1966
Primary
Juvela N

Approved Use

Accompanying symptoms resulting from the following Hypertension Hyperlipidemia Peripheral circulatory disturbance resulting from the following Arteriosclerosis obliterans

Launch Date

1966
Primary
Juvela N

Approved Use

Accompanying symptoms resulting from the following Hypertension Hyperlipidemia Peripheral circulatory disturbance resulting from the following Arteriosclerosis obliterans

Launch Date

1966
PubMed

PubMed

TitleDatePubMed
Patents

Sample Use Guides

The usual adult dosage for oral use is 300 - 600 mg of tocopherol nicotinate (3 - 6 capsules) daily in three divided doses
Route of Administration: Oral
In Vitro Use Guide
177 uM of Tocopherol led to decreased human platelet aggregation in response to the combined ADP and H2O 2
Name Type Language
TOCOPHERYL NICOTINATE
INCI   WHO-DD  
INCI  
Official Name English
TOCOPHERYL NICOTINATE, D-.ALPHA.
Preferred Name English
Tocopheryl nicotinate [WHO-DD]
Common Name English
3-PYRIDINECARBOXYLIC ACID, (2R)-3,4-DIHYDRO-2,5,7,8-TETRAMETHYL-2-((4R,8R)-4,8,12-TRIMETHYLTRIDECYL)-2H-1-BENZOPYRAN-6-YL ESTER
Common Name English
VITAMIN E NICOTINIC ACID ESTER
Common Name English
TOCOPHERYL NICOTINATE [INCI]
Common Name English
RENASCIN
Brand Name English
TOCOFERIL NICOTINATE [MART.]
Common Name English
.ALPHA.-TOCOPHEROL NICOTINATE, D-
Common Name English
VITAMIN E NICOTINATE
Common Name English
Code System Code Type Description
MESH
C012581
Created by admin on Fri Dec 15 15:36:40 GMT 2023 , Edited by admin on Fri Dec 15 15:36:40 GMT 2023
PRIMARY
ECHA (EC/EINECS)
256-101-7
Created by admin on Fri Dec 15 15:36:40 GMT 2023 , Edited by admin on Fri Dec 15 15:36:40 GMT 2023
PRIMARY
EPA CompTox
DTXSID1046396
Created by admin on Fri Dec 15 15:36:40 GMT 2023 , Edited by admin on Fri Dec 15 15:36:40 GMT 2023
PRIMARY
DAILYMED
WI1J5UCY5C
Created by admin on Fri Dec 15 15:36:40 GMT 2023 , Edited by admin on Fri Dec 15 15:36:40 GMT 2023
PRIMARY
SMS_ID
100000088059
Created by admin on Fri Dec 15 15:36:40 GMT 2023 , Edited by admin on Fri Dec 15 15:36:40 GMT 2023
PRIMARY
CAS
43119-47-7
Created by admin on Fri Dec 15 15:36:40 GMT 2023 , Edited by admin on Fri Dec 15 15:36:40 GMT 2023
PRIMARY
RXCUI
1359091
Created by admin on Fri Dec 15 15:36:40 GMT 2023 , Edited by admin on Fri Dec 15 15:36:40 GMT 2023
PRIMARY RxNorm
PUBCHEM
27990
Created by admin on Fri Dec 15 15:36:40 GMT 2023 , Edited by admin on Fri Dec 15 15:36:40 GMT 2023
PRIMARY
EVMPD
SUB15586MIG
Created by admin on Fri Dec 15 15:36:40 GMT 2023 , Edited by admin on Fri Dec 15 15:36:40 GMT 2023
PRIMARY
FDA UNII
WI1J5UCY5C
Created by admin on Fri Dec 15 15:36:40 GMT 2023 , Edited by admin on Fri Dec 15 15:36:40 GMT 2023
PRIMARY
DRUG CENTRAL
2689
Created by admin on Fri Dec 15 15:36:40 GMT 2023 , Edited by admin on Fri Dec 15 15:36:40 GMT 2023
PRIMARY